retatrutide updates Demand for Unapproved Weight-Loss Drug Surges on Social Media Retatrutide—A Game Changer in Obesity

I live in a world where there is no single best diet (much to the chagrin of low-carb and vegan diet acolytes) but this is what my experience suggests

Patients eligible to enter the trial were: 50 years of age or older and with established CV disease or CKD

However, some people find this effect stronger than expected initially

Abstract Glucagon-like peptide-1 (GLP-1) medicines reduce food intake, body weight, insulin resistance and inflammation, thus improving outcomes for people with type 2 diabetes and obesity and potentially contributing to decreased cancer incidence

If retatrutide produces better weight loss but costs significantly more, NICE may restrict it to specific patient groups while Mounjaro remains the first-line option